ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

9:00AM-11:00AM: Abstract Number: L02

Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study

Late-Breaking Posters

9:00AM-11:00AM: Abstract Number: 1578

Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing

Immunological Complications of Therapy Poster

9:00AM-11:00AM: Abstract Number: 1547

Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis

Imaging of Rheumatic Diseases Poster

9:00AM-11:00AM: Abstract Number: 1784

Roles and Perspectives of Partners of Women with Rheumatoid Arthritis on Reproductive Decision Making: A Constructivist Grounded Theory Study

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1776

Safety and Beneficial Effects of Hydroxychloroquine on Pregnancy Outcomes in Women with Systemic Lupus Erythematosus

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 1793

Safety of Obtaining Research Tissue During Clinically Indicated Kidney Biopsies: Data from the Lupus Accelerating Medicines Partnership

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1677

Schizophrenia Genetics and Neuropsychiatric Features in Childhood-Onset Systemic Lupus Erythematosus

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1824

Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1809

Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1822

Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy

SLE – Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1820

Serum α-Klotho Is Decreased in Older Systemic Lupus Erythematosus Patients and Correlate with Markers of Disease Activity

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

9:00AM-11:00AM: Abstract Number: 1660

Sleep Disturbance and Pain Severity and Multi-site Pain: A Prospective 10.7-year Follow-up Study

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1933

Small Vessel Vasculitis Surrounding a Preserved Temporal Artery: Search for Tissue Biomarkers with Potential Diagnostic Value

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1665

Sociodemographic and Clinical Predictors of Childhood-Onset SLE Disease Activity in the Childhood Arthritis and Rheumatology Research Alliance Registry

Pediatric Rheumatology – Clinical Poster III: SLE, Vasculitis, & JDM

9:00AM-11:00AM: Abstract Number: 1905

Soluble Guanylate Cyclase Reduced the Gastrointestinal Fibrosis in Bleomycin-induced Mouse Model of Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].